WASHINGTON UNIVERSITY, THE
Total received in grants · trailing 12 months
$13M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $401.9B in tracked grants
7separate grants, trailing 12 months
WASHINGTON UNIVERSITY, THE has received $13M across 7 federal grants of $1M or more on record.
Data as of August 5, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Energy | UNDERSTANDING AND CONTROLLING CELL-TO-CELL VARIABILITY FOR ROBUST BIOCONVERSION | $2,458,134 |
| Department of Energy | ENHANCING CARBON UTILIZATION BY ALGAL SYSTEMS VIA INTEGRATED BIOGAS PURIFICATION, NITROGEN REUSE, AND INNOVATIVE CARBON DIOXIDE DELIVERY | $2,222,518 |
| Department of Health and Human Services | DIAN-TU PRIMARY PREVENTION TRIAL - PROJECT SUMMARY THE DIAN-TU PLATFORM WAS FORMED TO DESIGN AND MANAGE INTERVENTIONAL THERAPEUTIC TRIALS AND FIND A TREATMENT THAT PROVIDES COGNITIVE BENEFIT FOR THOSE CERTAIN TO DEVELOP DOMINANTLY INHERITED AD (DIAD). THE DIAN-TU TRIAL PLATFORM IS NOW FULLY OPERATIONAL IN 16 COUNTRIES AND 40 SITES AND ACCOMMODATES 11 LANGUAGES. NIA FUNDING FOR THE DIAN-TU TRIAL PLATFORM ESTABLISHED THE INFRASTRUCTURE AND OPERATIONS FOR EXECUTING CLINICAL TRIALS IN DIAD AND ACKNOWLEDGED THE NEED FOR EVOLUTION WITHIN THIS PLATFORM. THE DIAN-TU PRIMARY PREVENTION TRIAL WILL LAY THE FOUNDATION FOR THE ULTIMATE TEST OF THE AMYLOID HYPOTHESIS AND PROVIDE THE BEST OPPORTUNITY TO PROVE THAT DEMENTIA IN THIS HIGHLY VULNERABLE POPULATION, AND POSSIBLY IN SPORADIC AD, CAN BE DRAMATICALLY MODIFIED, IF NOT PREVENTED ALTOGETHER. THE DIAN-TU PRIMARY PREVENTION TRIAL IS A FIRST OF ITS KIND, PHASE II/III, MULTI-STAGE RANDOMIZED, BLINDED PLACEBO-CONTROLLED (1:1) TRIAL IN 160 ASYMPTOMATIC DOMINANTLY INHERITED ALZHEIMER DISEASE MUTATION CARRIERS WHO ARE 11 TO 25 YEARS BEFORE THE ESTIMATED YEAR OF SYMPTOM ONSET (EYO) AND HAVE MINIMAL TO NO ASS-PIB PLAQUE BURDEN AT TRIAL ENTRY. THE FIRST THERAPY TESTED WILL BE WITH REMTERNETUG. THE RECENT FINDINGS IN THE FIELD FOR LECANEMAB AND DONANEMAB HAVE DEMONSTRATED THAT REMOVAL OF AMYLOID PLAQUES CAN REDUCE COGNITIVE DECLINE, REINFORCING THE NEED TO TEST TREATMENT BEFORE AMYLOID BEGINS TO ACCUMULATE IN THE BRAIN, I.E. PRIMARY PREVENTION. DIRECTLY TESTING THE AMYLOID HYPOTHESIS OF AD AND THE POTENTIAL IMPACT THE OUTCOMES COULD HAVE ON THE OVERALL BURDEN OF ALZHEIMER'S DISEASE (AD) IN THE U.S., THIS PROJECT ADDRESSES A MAJOR PUBLIC HEALTH PROBLEM. IN THIS STUDY, WE WILL TEST IF IT IS POSSIBLE TO PREVENT ASS DEPOSITION IN DIAD MUTATION CARRIERS AND IF DOING SO WILL PREVENT THE CASCADE OF PATHOLOGY ASSOCIATED WITH AD AND, ULTIMATELY, DEMENTIA IN A POPULATION THAT IS OTHERWISE CERTAIN TO GET THE DISEASE. THE RESULTS OF THIS STUDY ARE LIKELY TO BE HIGHLY IMPACTFUL ON THE AD FIELD IN ASSESSING THE ABILITY TO PREVENT AMYLOIDOSIS AND THE CONSEQUENCES OF DOING SO AT THE EARLIEST STAGES OF THE AD PATHOLOGICAL CASCADE. IF THE PREVENTION OF ASS PATHOLOGY IN DIAD IS ACCOMPLISHED, IT WILL PROVIDE ONE OF THE BEST SCIENTIFIC TESTS OF THE AMYLOID HYPOTHESIS AND PROVIDE THE BEST OPPORTUNITY TO PROVE THAT DEMENTIA IN THIS HIGHLY VULNERABLE POPULATION, AND POSSIBLY IN SPORADIC AD AND DOWN SYNDROME, CAN BE DRAMATICALLY MODIFIED. SHOULD PREVENTING AMYLOID PATHOLOGY FROM DEVELOPING HAVE NO IMPACT ON THE COURSE OF THE DISEASE, PARTICULARLY IN THIS POPULATION, THIS WOULD DIRECT FUTURE RESEARCH AND THERAPEUTICS TOWARDS OTHER MECHANISMS AND PATHOLOGIES. | $2,164,992 |
| Department of Energy | UPGRADING BIOGAS THROUGH IN SITU CONVERSION OF CARBON DIOXIDE TO BIOMETHANE IN ANAEROBIC DIGESTERS | $2,000,004 |
| Department of Energy | DE-EE0032178 NEW AWARD TITLED INTENSIFICATION OF HYDROGEN PRODUCTION ENABLED BY ELECTROCHEMICAL PUMPING MODULE FOR PURIFICATION AND COMPRESSION | $1,600,000 |
| Department of Health and Human Services | DEVELOPMENTAL PATHWAYS TO BORDERLINE PERSONALITY DISORDER: LONGITUDINAL OBSERVATIONAL, CLINICAL, AND NEURAL PREDICTORS FROM EARLY CHILDHOOD TO YOUNG ADULTHOOD - PROJECT SUMMARY BORDERLINE PERSONALITY DISORDER (BPD) IS A PROMINENT CONTRIBUTOR TO DISABILITY, BURDEN, AND INCREASED MORTALITY. ALTHOUGH IMPAIRMENTS IN SELF (RDOC SYSTEMS FOR SOCIAL PROCESSES: PERCEPTION AND UNDERSTANDING OF SELF) AND INTERPERSONAL (RDOC SYSTEMS FOR SOCIAL PROCESSES: AFFILIATION) FUNCTIONING ORIGINATE IN EARLY CHILDHOOD, LITTLE IS KNOWN ABOUT THE DEVELOPMENTAL PSYCHOPATHOLOGY OF THESE CORE FEATURES IN BPD, AS OPPOSED TO A RELATED PSYCHIATRIC DISORDER THAT OFTEN PRECEDES AND CO-DEVELOPS WITH BPD: MAJOR DEPRESSIVE DISORDER (MDD). THE CURRENT PROPOSAL WILL ESTABLISH DEVELOPMENTAL TRAJECTORIES OF INTERPERSONAL AND SELF DYSFUNCTION FROM EARLY CHILDHOOD INTO YOUNG ADULTHOOD, EXAMINING INTERACTIONS WITH ENVIRONMENTAL FACTORS AND ASSOCIATIONS WITH ABERRANT NEURAL CIRCUITRY, TO PREDICT ONSET OF BPD IN EARLY ADULTHOOD. IN THIS RENEWAL, WE LEVERAGE 17 YEARS OF PREVIOUSLY COLLECTED LONGITUDINAL DATA (R01 MH090786) FROM 348 YOUNG CHILDREN ENRICHED FOR EMOTIONAL DYSREGULATION. NOW YOUNG ADULTS (19-25 YEARS), 36% EXHIBIT BPD ABOVE DIAGNOSTIC THRESHOLD. THIS SAMPLE OFFERS AN UNPARALLELED OPPORTUNITY TO UNDERSTAND SPECIFIC DEVELOPMENTAL PRECURSORS FOR BPD ONSET. RICH PHENOTYPING, INCLUDING OVER A DECADE OF CLINICAL INTERVIEWS, NARRATIVES, QUESTIONNAIRES, OBSERVATIONS, AND REPEATED MRI AND EEG ASSESSMENTS MAKE THIS THE IDEAL AND HIGHLY COST-EFFECTIVE DATASET TO INVESTIGATE IMPAIRMENTS IN SELF AND INTERPERSONAL FUNCTIONING THAT LEAD TO BPD VERSUS MDD. NEW DATA COLLECTION IN YOUNG ADULTHOOD INCLUDES MULTI-METHOD ASSESSMENTS OF INTERPERSONAL AND SELF FUNCTIONING ALONGSIDE PSYCHIATRIC DIAGNOSTIC INTERVIEWS. OUR MOTIVATING HYPOTHESIS IS THAT IN THE CONTEXT OF EMOTION DYSREGULATION, PEER ACCEPTANCE AND AGGRESSION (INTERPERSONAL DYSFUNCTION) FROM PRESCHOOL THROUGH MIDDLE CHILDHOOD, INTERACTS WITH SELF-FUNCTIONING (UNSTABLE, INCOHERENT SELF-WORTH AND SELF- CONCEPT) IN ADOLESCENCE TO UNIQUELY PREDICT BPD ONSET IN ADULTHOOD VERSUS MDD. WE WILL EXAMINE: (1) HOW SPECIFIC ASPECTS OF THESE CONSTRUCTS PROSPECTIVELY RELATE TO ADULT BPD, AS OPPOSED TO CONTINUATION OF MDD; (2) DURING WHICH DEVELOPMENTAL PERIODS THESE CONSTRUCTS PROVIDE THE MOST PREDICTIVE UTILITY, INCLUDING THE MODERATING EFFECT OF SPECIFIC ENVIRONMENTAL FACTORS; AND (3) ASSESS THE PREDICTIVE AND MECHANISTIC ROLE OF NEURAL CORRELATES OF THESE CONSTRUCTS IN FORECASTING BPD VERSUS MDD. FINDINGS WILL INFORM THE OPTIMAL TIMING AND CONTENT-FOCUS (I.E., SPECIFIC NEURAL/BEHAVIORAL SELF AND INTERPERSONAL TARGETS) OF NOVEL EARLY-INTERVENTION FOR PREVENTING BPD DURING THE EARLIEST DEVELOPMENTAL PERIODS. THIS LONGITUDINAL RESEARCH WILL BE ABLE TO IDENTIFY RISK FACTORS FOR THE PERSISTENCE OR WORSENING OF INTERPERSONAL AND SELF DYSFUNCTION AND BPD ONSET, OFFERING THE BEST STARTING POINT TOWARD DEVELOPING A PREVENTION STRATEGY FOR BPD. | $1,405,361 |
| Department of Energy | WASHINGTON UNIVERSITY IN ST. LOUIS NEW CATALCHEM-E AWARD CONTROL NUMBER: 3505-1503 TITLE: TRINITY: A MULTIMODAL AI PLATFORM INTEGRATING DIGITAL, HIGH-THROUGHPUT, AND SCALE-UP TESTING FOR INVERSE CATALYST DEVELOPMENT THIS COMPETITIVE COOPERATIVE AGREEMENT FOR A RESEARCH AND DEVELOPMENT PROJECT ENTITLED, “TRINITY: A MULTIMODAL AI PLATFORM INTEGRATING DIGITAL, HIGH-THROUGHPUT, AND SCALE-UP TESTING FOR INVERSE CATALYST DEVELOPMENT” IS AWARDED WASHINGTON UNIVERSITY IN ST. LOUIS UNDER ARPA-E FOA NUMBER DE-FOA-0003505(CATALCHEM-E ) AND CONTROL 3505-1503. THE PURPOSE OF THIS AWARD IS TO DEVELOP A LASER FURNACE TO CONVERT IRON ORE INTO IRON METAL WITHOUT EMITTING CARBON DIOXIDE, AT LOWER COST THAN THE BLAST FURNACE. OUR MISSION IS TO REPLACE FOSSIL FUELS TRADITIONALLY USED IN IRONMAKING WITH LASERS POWERED BY CLEAN ELECTRICITY. AT THE CORE OF LIMELIGHT STEEL’S PROCESS ARE SEMICONDUCTOR LASER DIODES, WHICH ENABLE NEW TEMPERATURE AND PRESSURE RANGES TO REDUCE HIGH AND LOW-GRADE IRON ORE FINES INTO MOLTEN IRON METAL. | $1,361,250 |